Phase 3 results posted: Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction — LIB Therapeutics LLC
Why now
Thesis: Cholesterol drug results shape lipid-therapy competition
Catalyst to watch: Regulatory filing by LIB Therapeutics
Main risk: Data may show insufficient efficacy
Why it matters
Completed Phase 3 results for a cholesterol drug inform a potential competitive entrant.
Details
Sponsor: LIB Therapeutics LLC; Status: Completed; Conditions: Heterozygous Familial Hypercholesterolemia; Interventions: lerodalcibep; Enrollment: 478 (actual); First posted: 2021-03-15; Results posted: 2026-09-28; NCT: NCT04797104
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-28 12:00 UTC